Cellumed Expands Global Raw Material Supply Chain... Stable Supply of High-Quality Human Tissues Expected

Cellumed, a subsidiary of the InskoBi Group specializing in the manufacturing of bio-medical devices, announced on May 14 that it had signed a business agreement with an overseas company to ensure stable production of its flagship products?bone formation therapeutics and skin graft materials?and to strengthen its global raw material supply chain.

The reinforcement of the raw material supply chain is part of a strategy to respond to market expansion resulting from an aging population and increased demand for orthopedic and reconstructive surgeries. The company aims to build a more stable raw material supply chain by maintaining trust with existing suppliers while also entering into new contracts with overseas suppliers that meet global standards.

Through the stable supply of raw materials, Cellumed expects not only to reduce costs but also to decrease risks associated with supply instability and to enhance production efficiency by enabling more flexible production planning. In particular, with production facility processes improved earlier this year, resulting in up to a twofold increase in production capacity (CAPA), the strengthened raw material supply chain is expected to further bolster the company's sales competitiveness by allowing it to respond swiftly to market demand.

Cellumed anticipates sales growth and improved profitability based on its competitive advantages in timely production and distribution, increased customer satisfaction, and the acquisition of new clients.

A Cellumed representative stated, "The bone formation and skin graft sectors are high value-added fields with steadily increasing demand both domestically and internationally, and a stable raw material supply chain is the key to competitiveness. Through this supply chain reinforcement, we plan to further expand our market leadership by enhancing quality and productivity."

Meanwhile, there has been a recent trend of increasing imports of human tissues from overseas, due to factors such as an aging population, advances in transplantation technology, and the higher safety of these materials compared to xenografts and synthetic grafts.

According to the Ministry of Food and Drug Safety, in 2023, imports of human tissues from overseas reached 942,908 units, accounting for 91.6% of the total domestic volume, while domestic human tissue donations amounted to 86,974 units (8.4%). The bone formation therapeutics and skin graft materials sold by Cellumed use imported human tissues as core raw materials, and the stable procurement of these raw materials is considered a key factor directly impacting production volume, product quality, and supply speed.

This content was produced with the assistance of AI translation services.